Abstract Library

#4631 Correlations between dosimetry and imaging in patients with neuroendocrine tumour treated with 177Lu-DOTATATE

Introduction: Tumour dose may be an important predictor of clinical response, but estimation of a clinically relevant tumour-absorbed dose without high risk of toxicity is challenging.

Conference:

Presenting Author: Gomez Sanchez D

Authors: Gomez Sanchez D, Ribelles M, Fernandez Iglesias A, Paruta Araez L, Mata E,

Keywords: dosimetry, 177Lu-DOTATATE,

#3342 Dosimetry evaluation in 177Lu-labeled somatostatin analogue therapy

Introduction: In this paper a dosimetric study of 177Lu-labeled somatostatin analogue (177Lu-DOTATOC) therapy was described.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Cichoński A, Kempińska Wróbel M, Ćwikła J,

Keywords: internal dosimetry, radioisotope therapy, MIRD,

#3275 MicroRNA prognostic signature in neuroendocrine neoplasias (NENs) of lung and GEP origin: In silico analysis of target genes and pathways

Introduction: Molecular knowledge of NENs has increased in the last years. Nevertheless, the lack of in vivo models makes it difficult to guide functional experiments to better understand the biological implications of described molecular alterations. In this context, and as miRNAs contribute to regulate gene expression, we performed an in silico analysis to explore target genes and involved pathways regulated by an 8-miRNA prognostic signature that we recently developed in NENs, that stratified patients in 3 prognostic groups (Espinosa-Olarte P et al, ESMO 2020).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Espinosa Olarte P, Soldevilla B, Carretero-Puche C, Molina-Pinelo S, Robles C,

Keywords: neuroendocrine neoplasia, miRNAs, genes, pathways, prognosis,

#1156 Characterisation, Measurement and Biodistribution of an Improved Formulation of [Lu-177]-Octreotate

Introduction: Lu-177 can be made with high specific activity and no other isotopes of lutetium present, referred to as “no carrier added” (nca) Lu-177. We have radiolabelled DOTA-conjugated peptide DOTA‐(Tyr3)‐octreotate (Auspep, Melb., AUS) with nca Lu-177 (“nca-LuTATE”) and used it in over 30 administrations in NETs patients.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Bailey D

Authors: Bailey D, Willowson K, Hennessy T, Schembri G, Snowdon G,

Keywords: lutetium, dosimetry, biodistribution, effective dose,

#781 Effect of Mean Absorbed Renal Dose on the Renal Function After Peptide Receptor Radionuclide Therapy

Introduction: Kidneys are the critical organs in peptide receptor radionuclide therapy (PRRNT) of neuroendocrine neoplasms (NENs).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Kulkarni H, Schuchardt C, Wiessalla S, Senftleben S, Baum R,

Keywords: mean absorbed renal dose, renal toxicity, peptide receptor radionuclide therapy,